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Interferon-g (IFN-g) directs T helper-1 cell differentiation and mediates antitumour effects in preclinical models. However, high-dose
IFN-g is toxic in vivo, and IFN-g-transfected neuroblastoma (NB) cells secreting high amounts of the cytokine may be lost due to cell
apoptosis or differentiation. Two human NB cell lines (ACN and SK-N-BE2(c)) differing as to genetic and phenotypic features were
transfected with the human IFN-g gene and selected on the grounds of the low concentrations of IFN-g produced. In both IFN-g-
transfected cell lines, autocrine and paracrine activation of IFN-g-mediated pathways occurred, leading to markedly reduced
proliferation rate, to increased expression of surface HLA and CD40 molecules and of functional TNF binding sites. ACN/IFN-g cells
showed a significantly delayed tumorigenicity in nude mice as compared to parental cells. ACN/IFN-g tumours were smaller, with
extensive necrotic area as a result of a damaged and defective microvascular network. In addition, a significant reduction in the
proliferation index was observed. This is the first demonstration that IFN-g inhibits in vivo proliferation of NB cell by acting on the
tumour cell itself. This effect adds to the immunoregulatory and antiangiogenic activities operated by IFN-g in syngeneic tumour-
bearing hosts.
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Neuroblastoma (NB), the most frequent extracranial solid tumour
of childhood, arises from the neural crest, and the prognosis for
patients presenting with disseminated disease at diagnosis is poor
despite multimodal aggressive therapy (Brodeur et al, 1993).
Immunisation of cancer patients with cytokine-engineered
tumour cells has been investigated at preclinical and clinical levels
(Forni and Boggio, 1999; Pardoll, 2000; Parmiani et al, 2000;
Wadhwa et al, 2002).
Several preclinical studies, performed in syngeneic mice with
murine NB cell lines engineered to express different cytokines
(Watanabe et al, 1989; Katsanis et al, 1994; Bausero et al, 1996),
HLA antigens (Hock et al, 1995, 1996; Heuer et al, 1996; ) or
costimulatory molecules (Katsanis et al, 1995; Heuer et al, 1996;
Katsanis et al, 1996; Grossmann et al, 1997), have shown the
therapeutic efficacy of this approach. In a xenogeneic model, we
have previously shown that IL-2-transfected human NB cells
inhibited the growth of parental tumour cells coinjected in nude
mice (Corrias et al, 1998).
So far, three different phase I trials have been performed in NB
patients unresponsive to conventional treatments, by employing
either autologous or allogeneic NB tumour cells engineered to
produce IL-2, alone or in combination with lymphotactin (Brenner
et al, 2000; Rousseau et al, 2003; Bowman et al, 2003). In these
trials, some of the vaccinated patients showed increase in leucocyte
count, antibody levels and in NK activity.
Among the cytokines so far investigated, interferon (IFN)-g
appears to be of particular interest due to its ability to upregulate
surface expression of HLA class I molecules in human NB cells
(Lampson et al, 1983; Ponzoni et al, 1993; Corrias et al, 2001) and
to activate cytotoxic T-lymphocyte-mediated antitumour re-
sponses in a murine model (Watanabe et al, 1989).
However, studies in humans have shown that high-dose
recombinant IFN-g administration is associated with serious
side effects. Local low-dose release of cytokines, obtainable
by gene transfer, may overcome systemic toxicity without
impairing immune recognition of malignant cells by the
immune system. In small cell lung carcinoma, a tumour
that displays a downregulation of HLA class I antigen and
shares neuroectodermal origin with NB, IFN-g transfection
have been demonstrated to enhance HLA class I surface expres-
sion and restore presentation of a MAGE-3 peptide to CTL
(Traversari et al, 1997).
This approach appears feasible also for human NB cells since NB
tumours express CTL-defined TAA, such as tyrosine hydroxylase
((Lode et al, 2000), MAGE-1 and 3 (Rimoldi et al, 1993; Corrias
et al, 1996), NY-ESO (Soling et al, 1999; Rodolfo et al, 2003) and
ALK (Lamant et al, 2000), and tumour-specific cytolytic T
lymphocytes have been isolated from NB-bearing patients
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Rousseau et al, 2003).
In addition to serving as an immunostimolatory molecule and
exerting antiangiogenic effects through IP-10 production (Sgadari
et al, 1996), IFN-g can sensitise tumour cells to apoptosis (Fulda
and Debatin, 2002). Furthermore, it can induce expression of
functional surface CD40 molecules on NB cells (Airoldi et al, 2003),
making them susceptible to CD40L-mediated apoptosis.
In this study, we have established and characterised in vitro two
low-dose IFN-g-producing NB cell lines, which differ in their
genetic and phenotypic features. Furthermore, we have tested
tumorigenicity of ACN/IFN-g cell lines in a xenogeneic transplant
model in nude mice and have addressed the mechanisms for
delayed tumorigenicity.
MATERIALS AND METHODS
Vectors and cell lines transfection
The human IFN-g cDNA was amplified by RT–PCR starting from
1mg of total RNA extracted from PHA-activated peripheral blood
lymphocytes. The sequences of PCR primers were: forward
TGACAGGCTTAATTCTCTCGGAAACG, reverse TAGACTTAG-
GATCCAATATTGCAGGCAGGACAACC; a BamHI site is under-
lined. The cDNA was cloned in the XbaI blunted-BamHI sites of
plasmid RSV.5 neo (kindly provided by Dr EO Long, NIH,
Bethesda, MD, USA). Both ACN and SK-N-BE2(c) cell lines were
transfected with 5mg of the RSV.5IFN-g (later refered as ACN/IFN-
g and SK/IFN-g) or RSV.5 (later refered as ACN/neo and SK/neo)
using cationic liposomes (DOTAP, Roche, Milano, Italy), accord-
ing to instructions provided by the manufacturer. Stable
transfectants were selected by growing the transfected cells in a
medium containing 500mgml
 1 of G-418 (Calbiochem, La Jolla,
CA, USA).
RNA extraction, RT–PCR analysis and RNAse protection
assay (RPA)
Total RNA was extracted using the RNeasy extraction kit (Qiagen,
Hilden, Germany). In all, 1mg of total RNA, resuspended in sterile
water, was retrotranscribed with oligo d(T) by means of a
commercial kit according to the procedure suggested by the
manufacturer (Clontech, Palo Alto, CA, USA). At the end of the
synthesis, the cDNA was diluted to 100ml and then 5ml was
separately amplified with primers specific for IFN-g, IP-10, IRF-1,
NY-ESO, MAGE-1 and 3, TH, MYC-N, ALK and for the
housekeeping gene G3PDH. The primers sequences, positions
and accession number of the different sequences, size of the
amplification products and annealing temperature are given in
Table 1. All the amplifications were performed for 35 cycles, after
10min at 941C to activate AmpliTaq gold polymerase (Perkin-
Elmer Apllied Biosystem, Norwalk, CT, USA). Amplified products
were analysed in a 2% agarose gel run in TBE buffer and stained
with ethidium bromide. Specificity of the amplified products was
determined by direct sequencing performed with the use of the
Dye Terminator Cycle Sequencing Kit (ABI PRISM; Perkin-Elmer
Applied Biosystem). Sequences were resolved and analysed on the
ABI373A Sequence Apparatus (Perkin-Elmer Applied Biosystem).
RNAse protection assay was performed with 5mglane
 1 total
RNA and the Pharmingen probe hCR-3 kit (Pharmingen, San
Diego, CA, USA), according to manufacturer’s protocol. Products
were resolved on 6% denaturing polyacrylamide gels and the
protected fragments were visualised and quantitated using a
PhosphorImager 445SI (Molecular Dynamics, Sunnyvale, CA,
USA).
Flow cytometry and cell cycle analysis
Surface expression of HLA molecules was analysed by indirect
immunofluorescence and cytofluorimetric analysis using the
W6.32mAb (anti HLA I, kindly provided by Dr S Ferrone, Roswell
Park Cancer Center, Buffalo NY, USA) and the D1.12mAb (anti
HLA II, kindly provided by Dr R Accolla, University of Insubria,
Italy). An FITC-conjugated goat anti mouse IgG2a was used as
second-step reagent. Surface expression of CD40 was analysed by
means of PE-conjugate anti CD40mAb from Diaclone SA,
Besanc¸on, France. Controls for anti HLA I and HLA II were
purified murine IgG2a (Southern Biotechnologies Associates,
Birmingham, AL, USA) of irrelevant specificity. Control for anti-
CD40 was PE-conjugated, isotype-matched mAb of irrelevant
specificity. Intracellular staining for anti Ki-67 was performed by
incubating cells in PBS containing 0.1% saponin and anti Ki-67
antibody (clone MIB-1, Dako, Glostrup, Denmark) or the
corresponding control isotype (purified murine IgG1 of irrelevant
specificity from Southern Biotechnologies Associates). An FITC-
conjugated goat anti mouse IgG1 was used as second-step reagent.
Samples were analysed with the FACScan (BD Biosciences-
Mountain View, CA, USA). Cells were scored using a FACScan
analyzer (Becton-Dickinson, San Jose, CA, USA) and data were
processed using CellQuest software (Becton-Dickinson). The
threshold line was based on the maximum staining obtained with
irrelevant isotype-matched mAb, used at the same concentration
as test mAb. Negative cells were defined such that less than 1% of
cells stained positive with control mAbs. Cells labeled with test
antibody that were brighter than those stained with isotypic
control antibody were defined as positive.
Cell cycle analysis was performed by incubating 10
5 cells in PBS
containing 40mgml
 1 propidium iodide, 0.1% Triton X-100 and
400mgml
 1 RNase A for 10min at 371C. Cells were analysed by
flow cytometry using CellQuest software, after 10 additional
minutes at room temperature.
Cytokine production
Supernatants of semiconfluent, G418-resistant, IFN-g-transfected
NB cells were collected after 48h and analysed for human IFN-g
Table 1 Sequence of primers used in RT–PCR analysis and size of the amplification products
Gene Accession no. Forward Position Reverse Position Temp Bp
IFN-g X13274 50ATTGAATTCACGATGAAATATACAAGTTA 106–125 50-ATTCTCGAGCAGGCAGGACAACCATTACT 605–624 601C 518
IP-10 X02530 50-GGAACCTCCAGTCTCAGCACC 46–66 50-GGATGATGAACATTAACCTTCC 536–559 581C 513
IRF-1 NM_002198 50-GCTCCACTCTGCCTGATGACC 658–678 50-GAGGAATAAGAGGGGCCCAGG 1183–1203 591C 545
TH NM_000360 50TGTCAGAGCTGGACAAGTGT 528–547 50-GATATTGTCTTCCCGGTAGC 826–807 601C 299
MAGE1 AY148486 50-CGGCCGAAGGAACCTGACCCAG 1–22 50-GCTGGAACCCTCACTGGGTTGCC 399–421 601C 420
MAGE3 HSU03735 50-TGGAGGACCAGAGGCCCCC 2276–2294 50-GGACGATTATCAGGAGGCCTGC 3059–3080 601C 804
NY-ESO NM_001327 50GCCGCCTGCTTGAGTTCTAC 342–361 50-CTCCTCCAGCGACAAACAAT 718–737 601C 395
MYC-N NM_005378 50TGTCGGTTGCAGTGTTGGAGG 22–42 50-TGTCGGTTGCAGTGTTGGAGG 247–267 601C 245
ALK XM_055726 50-GCTGAGCAAGCTCCGCACCTCGAC 4144–4167 50-CCCGCCATGAGCTCCAGCAGGATG 4486–4509 601C 365
GAPDH NM_002046 50-ACATCGCTCAGAACACCTATGG 16–37 50-GGGTCTACATGGCAACTGTGAG 1191–1212 601C 1196
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Minneapolis, MN, USA). Cells were counted and results are
referred to 48h production from 10
6 cells.
TNF-a receptor binding assay
Cells were seeded in triplicate at a density of 10
6 well
 1 in 2ml
medium in six-well plates. After 24h, cells were washed twice and
then incubated for 2h at 41C in cold medium containing 80–
120pM
125I-labeled hrTNF-a (Sorin Pharmaceuticals, Verona, Italy)
in the presence or absence of increasing concentrations of
unlabelled hrTNF-a (a generous gift of Boehringer Mannheim,
Mannheim, Germany). Afterwards, cells were washed twice with
ice-cold medium, detached with ice-cold PBS and washed twice by
centrifugation. The pellet-associated
125I was counted in a g-
counter (LKB, Uppsala, Sweden) with an estimated efficiency of
80%. Cell number was determined by counting cells in a
hemocytometer. To evaluate the binding affinity and number of
site per cell, the ligand displacement curves were subjected to
Scatchard analysis by means of the Ligand program by considering
TNF-a as a trimer, as previously described (Montaldo et al, 1994).
Coculture of parental and IFN-c-transfected cells
Parental cells (5 10
5) were seeded on the bottom plate and
5 10
5 of either the empty vector- or the IFN-g-transfected cells
were seeded on the upper plate of a transwell (Costar, Cambridge,
MA, USA). The two chambers were separated by a policarbonate
filter with pore size of 0.4mm. Afterdays of coculture, the upper
well was discarded and the parental cells on the bottom plate were
detached and analysed by flow cytometry or by RT–PCR analysis.
Nude mice studies
Pathogen-free female athymic (nu/nu) mice, 6–8 weeks old, were
obtained from Harlan Italy (San Pietro al Natisone, Italy). Animal
experiments, performed according to the National Regulation on
Animal Research Resources, were approved by the Review Board
of the Istituto Nazionale per la Ricerca sul Cancro. Mice were
housed under sterile conditions and received autoclaved food and
water. Animals (seven for each group) were injected subcuta-
neously with 2 10
7 parental ACN or transfected ACN/neo or
ACN/IFN-g cells. Tumour size, measured twice a week with a
caliper, was expressed as a multiple of the wider and smaller
diameters. Statistical analysis was performed by the Mann–
Withney test.
Morphological analysis
ACN/neo and ACN/IFN-g tumours were removed at day 14 post
injection (p.i.), fixed in 10% neutral-buffered formalin, embedded
in paraffin, sectioned at 4mm, and stained with haematoxylin–
eosin for histological evaluation. For immunohistochemistry,
formalin-fixed, paraffin-embedded sections were incubated with
anti-human Ki-67 (clone MIB-1, Dako) or anti laminin (Ab No.
078P, BioGenex, San Ramon, CA, USA) Abs. The rates of
proliferating (immunoreactivity for Ki-67) cells were obtained by
counting the number of positive cellsper number of total cells in
the viable neoplastic tissue excluding areas of tissue necrosis under
a microscope at  400 in a 0.180mm
2 field. Differences in the
number of Ki-67-positive cells were evaluated by Student’s t-test.
RESULTS
Stable IFN-c transfection of NB cell lines
Several NB cell lines were transfected with the recombinant
RSVneo/human IFN-g gene or the empty vector. All the
Figure 1 IFN-g and IP-10 gene expression in parental and IFN-g -
transfected NB cell lines. RT–PCR analysis performed on parental, empty
vector- and IFN-transfected SK-N-BE2(c) (lanes 1–3) and ACN (lanes 4–
6) cells, and water as negative control (lane 7). Size of the expected
fragments is indicated on the left. G3PDH amplification products are shown
in the lower panel. M¼Fw174 Hae/digest molecular weigh marker.
Figure 2 In vitro effects of IFN-g transfection on NB cells. (A) Doubling
time of IFN-g-transfected, empty vector-transfected and parental NB cells,
assessed by counting cells every day for a week (B) Proliferation index of
ACN, ACN/IFN-g and ACN/neo, assessed by Ki-67 staining. (C) Cell cycle
analysis of ACN/IFN-g (left panel) and ACN/neo (right panel) cells. (D) HLA
class I surface expression of SK/IFN-g cells (dark profile: SK/neo; open profile:
SK/IFN-g). (E) HLA class II surface expression of ACN/IFN-g cells (dark
profile: ACN/neo; open profile: ACN/IFN-g), as assessed by flow cytometry.
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natants higher than 25pgml
 148h 10
6 cells
 1were excluded from
the study. Two stable, low-dose IFN-g-producing transfected cell
lines, ACN and SK-N-BE2(c), were established. ACN cells lack
MYC-N amplification and 1p3.6 deletion (Thiele, 1999), but
express MAGE-1 and -3 (Corrias et al, 1996), as well as NY-ESO
and ALK (this paper, see below). In addition, ACN cells are
tumorigenic in nude mice (Corrias et al, 1998). On the contrary,
SK-N-BE2(c) cells are MYC-N amplified and 1p deleted (Thiele,
1999), express MYC-N and TH (this paper, see below) and are not
tumorigenic in nude mice.
Both stable IFN-g transfectants expressed human IFN-g-specific
transcripts when tested by RT–PCR (Figure 1). IFN-g production
in culture supernatants from IFN-g-transfected ACN and SK-N-
BE2(c) cells was 19.2 and 18.5pgml
 148h
 110
6 cells
 1, respec-
tively, as assessed by ELISA.
In vitro characterisation of IFN-c transfectants
IFN-g-transfected cells from both the cell lines displayed a more
differentiated phenotype, that is presence of neurites, than their
parental counterparts (data not shown), as observed following
treatment with hr IFN-g (Ponzoni et al, 1992).
IFN-g transfection activated IFN-regulated pathways in both NB
cell lines, as indicated by de novo expression of the IFN-inducible
IP-10 gene transcript (Figure 1). Moreover, both ACN/IFN-g and
SK/IFN-g transfectants displayed a dramatic increase in their
doubling time, as evaluated by cell count (Figure 2A). In order to
understand the mechanism(s) underlying cell growth inhibition,
we analysed the effect of released IFN-g on proliferation rate and
apoptosis. IFN-g transfection significantly (Po0.005) reduced the
proliferation rate, assessed by Ki-67 staining, of ACN/IFN-g cells,
as compared to parental and vector-transfected cells (Figure 2B).
Indeed, cell cycle analysis showed that ACN/IFN-g cells were
mostly arrested in G0/G1 phase (Figure 2C), as compared to
vector-transfected ACN/neo cells. On the contrary, IFN-g transfec-
tion did not significantly modify the amount of apoptotic cells in
culture (data not shown). Similar results were obtained with the
SK-N-BE2(c) transfectants (data not shown).
IFN-g transfection induced, in both cell lines, remarkable changes
in surface expression of HLA molecules. In the SK-N-BE2(c) cell line,
which constitutively expresses very low amounts of HLA class I and
no HLA class II molecules (Corrias et al, 2001), IFN-g transfection
produced a clear-cut increase in HLA class I antigen (Figure 2D) and
no changes in HLA class II expression (not shown) with respect to
SK/neo cells. In the ACN cell line, which constitutively expresses
HLA class I and low amounts of HLA class II molecules (Corrias etal,
2001), increased expression of HLA class II antigens was detected
(Figure 2E) with respect to the ACN/neo cells.
Consistent changes also occurred in the surface expression of
TNF-a binding sites, as assessed by Scatchard analysis using
radiolabelled hrTNF-a (Ponzoni et al, 1992; Montaldo et al, 1994).
Table 2 Growth rate, TNF receptor surface expression and effect of TNF-a treatment on growth rate of parental, vector- and IFN-transfected NB cells
Proliferation
TNF-a binding sites per cell
a Medium
b +TNF-a
b Mean percentage of inhibition
ACN 310715 47327216 33327287 24.8
ACN/neo 306716 45457244 35727196 22.3
ACN/IFN-g 942736 38377322 22437312 41.5
SK-N-BE 2(c) 129711 49557269 19447103 58.3
SK/neo 132712 46437268 21877259 57.4
SK/IFN-g 467726 40517266 15987327 69.5
asee Materials and Methods for details on Scatchard analysis.
b1h[
3H]thymidine incorporation measured in 5 10
4 cells cultured for 2 days in medium or in medium containing
hrTNF-a at 100IUml
 1. All the results are the mean7s.d. of three independent experiments, each carried out in duplicate.
Figure 3 Effects of IFN-g transfection on cocultured parental NB cells.
(A) RT–PCR analysis of IRF-1 gene expression. M¼molecular weigh
markers. Negative control (lane 1), ACN cells (lane 2), ACN/IFN-g cells
(lane 3), ACN cells cocultured with ACN/IFN-g cells (lane 4), SK-N-BE2(c)
cells (lane 5), SK/IFN-g cells (lane 6), SK-N-BE2(c) cocultured with SK/IFN-g
cells (lane 7). G3PDH gene expression is shown below. Size of the
expected fragment is indicated on the left side. (B) HLA class I surface
expression of parental SK-N-BE2(c) cells cocultured with SK/IFN-g cells for
72h (dark profile: irrelevant murine IgG2a; open profile anti HLA I
W6.32mAb). (C) HLA class II surface expression of parental ACN cells
cocultured with ACN/IFN-g cells for 72h (dark profile: irrelevant murine
IgG2a; open profile: anti HLA II D1.12mAb). (D) CD40 surface expression
of parental ACN cells cocultured with ACN/IFN-g cells for 72h (dark profile:
PE-conjugated mAb of irrelevant specificity; open profile: PE-conjugated
anti CD40mAb). (E) Ki-67 staining of ACN cells cocultured with ACN/IFN-
g (open profile) or ACN/neo (grey profile), as assessed by flow cytometry.
Dark profile: ACN cells stained with an isotype-matched irrelevant mAb.
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more binding sites than parental and empty vector-transfected
cells. Furthermore, when the IFN-g transfectants were treated with
hrTNF-a, their growth rate was further reduced (Table 2).
Inhibition of cell proliferation was higher than that observed in
the parental or empty vector-transfected cells (Table 2), although it
was more evident for ACN/IFN-g cells than for SK/IFN-g cells.
These findings confirmed the occurrence of a synergistic effect
between IFN-g and TNF-a at inducing differentiation of NB cells
(Ponzoni et al, 1992; Montaldo et al, 1994).
Effect of IFN- c released by IFN-c transfectants on
cocultured parental cells
To test whether the low amounts of IFN-g released by IFN-g
transfectants was sufficient to upregulate, by a paracrine mechan-
ism, IFN-g-inducible gene expression in the parental cells,
coculture in a transwell system was performed.
Both parental cell lines showed induction of IRF-1 gene
expression, as assessed by RT–PCR analysis, upon coculture for
3 days with the corresponding IFN-g transfectants (Figure 3A).
IRF-1 is the transcription factor necessary and sufficient to
enhance expression of all the IFN-g-inducible genes (Loh et al,
1992). Following coculture with paired IFN-g transfectants,
parental SK-N-BE2(c) cells expressed HLA class I molecules
(Figure 3B) and parental ACN cells HLA class II molecules
(Figure 3C). No modification in HLA surface expression was
observed when the parental ACN and SK-N-BE2(c) cells were
cocultured with the empty vector-transfected cells (not shown).
We have recently demonstrated that treatment of several NB cell
lines with hrIFN-g induced surface expression of CD40 (Airoldi
et al, 2003). ACN/IFN-g also showed enhanced CD40 gene and
surface expression (Airoldi et al, 2003). ACN/IFN-g cells cocultured
with parental ACN cells induced CD40 surface expression on these
latter cells (Figure 3D), further confirming that a paracrine effect
was produced by the low amount of IFN-g released by the NB
transfectants. Similar results were obtained when ACN cells were
cocultured with SK/IFN-g cells and, conversely, the latter cells were
cocultured with ACN/IFN-g cells (data not shown).
Finally, IFN-g released by ACN/IFN-g transfectants significantly
reduced (Po0.005) the proliferation rate of cocultured parental
ACN cells, as assessed by Ki-67 staining (Figure 3E). No change in
the percentage of apoptotic cells was observed under this conditions
(data not shown). Similar results were obtained in parental SK-N-
BE2(c) cells cocultured with SK/IFN-g (data not shown).
Expression of TAA genes in IFN-c-transfected NB cells
Next, we investigated the effects of IFN-g transfection on the
expression of different TAA genes, as assessed by RT–PCR. As
Figure 4 TAA gene expression in parental and transfected NB cell lines.
RT–PCR analysis performed on parental, empty vector- and IFN-
transfected SK-N-BE2(c) (lanes 1–3) and ACN (lanes 4–6) cells and
water as negative control (lane 7). Size of the expected fragments is
indicated on the left. G3PDH amplification products are shown in the
lower panel. M¼Fw140 Hae/digest molecular weigh marker.
Figure 5 Cytokine receptor gene expression in parental and IFNg-
transfected ACN cells as assessed by RPA. RNase protection assay was
performed with 5mglane
 1 total RNA and the Pharmingen probe hCR-3 kit.
Figure 6 Growth rate, histological and immunohistochemical features of parental, ACN/neo and ACN/IFN-g cells in nude mice. (A) Growth rate in vivo.
2 10
7 parental (J-J), vector-transfected (&-&) or IFN-transfected ACN (B-B) cells were inoculated subcutaneously in the left flank of nude mice.
Tumour growth was measured twice a week with a caliper. Results are the mean of two independent experiments, each one performed with five animals
per group. (B) Photograph of ACN/neo and ACN/IFN-g tumours taken 14 days post injection (p.i.). (C) Histological and immunohistochemical analysis of
ACN/neo and ACN/IFN-g tumours developed 14 days p.i. H&E: ACN/neo and ACN/IFN-g tumour sections stained with haematoxylin–eosin. Small nests of
round to oval cells with abundant amphophilic cytoplasm and nucleolated nuclei are shown. ACN/IFN-g tumours showed extensive areas of necrosis (N)
frequently infiltrated by reactive cells (arrows). Ki-67: Tumour sections stained with anti Ki-67mAb. Laminin: Tumour sections stained with anti-laminin mAb.
Magnification is  400.
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of MYC-N, ALK and TH genes as parental SK and SK/neo cells,
while ACN/IFN-g cells displayed expression of ALK, NY-ESO,
MAGE-1 and -3 mRNAs as parental ACN and ACN/neo cells
(Figure 4).
Expression of cytokine receptor genes in IFN-c-transfected
NB cells
We next tested by RNAse protection assay whether IFN-g
transfection modified gene expression of different cytokine
Transfection of NB cell lines with human IFN-c gene
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IFN-g cells showed enhanced mRNA expression of IFN-g
receptor (R) a, IL-6Ra, IL-11R and IL-12Rb2. Notably, ACN
and SK-N-BE2(c) cells did not express IL-12Rb1, irrespective
of IFN-g gene transfection (Figure 5). In addition, expression
of two proinflammatory cytokines, IL-8 and TNF-a, known to
be expressed by NB cell lines (Nitta et al, 1994; Yang et al,
1994), and of two anti-inflammatory cytokines, IL-10 and
TGF-b1, known to inhibit antitumour responses (Hsieh et al,
2000) was not modified by IFN-g gene transfection (data not
shown).
Tumorigenicity of ACN/IFN-c in nude mice and
histopathological features of tumours
Species specificity of IFN-g and IP-10 does not allow one to test
elicitation of antitumour responses in immunodeficient mice
bearing human IFN-g-transfected cells. Therefore, we tested
whether IFN-g transfection affected the tumorigenicity of ACN
cell line by acting through autocrine and paracrine mechanisms at
the level of the tumour cell themselves. Parental, ACN/neo and
ACN/IFN-g cells were injected subcutaneously in nude mice and
tumour growth was measured. The in vivo growth of ACN/IFN-g
cells was significantly (Po0.005) slower than that of parental or
vector-transfected ACN cells in vivo (Figure 6A). To address
whether this was a consequence of reduced proliferation rate,
histopatological analyses were performed on tumours removed at
days 14 post injection, when macroscopic differences in the
volume of the ACN/IFN-g and ACN/neo tumours were observed
(Figure 6B).
The tumour masses developed 14 days after s.c. injection of
ACN/neo cells into nu/nu mice were formed by small nests of
closely packed round or oval cells with abundant amphophilic
cytoplasm and vesciculated nuclei containing one or more
conspicuous nucleoli (Figure 6C, H&E). The pattern of growth
was vaguely nodular as a result of the presence of delicate,
incomplete fibrous septa. Small necrotic foci were a rather
constant feature. However, mitotic figures were also frequent
(Figure 6C, H&E).
Mice injected with ACN/IFN-g cells developed tumours, which
were smaller in size (Figure 6B) and showed extensive necrotic
areas (Figure 6C, H&E, N) often infiltrated with granulocytes and
macrophages phagocyting cell debris (Figure 6C, H&E arrows).
The proliferation index, assessed by Ki-67 immunoreactivity in the
viable neoplastic tissue excluding areas of tissue necrosis, was
significantly lower (Po0.005) than in ACN/neo tumours (66.574.0
vs 80.275.4%) (Figure 6C, Ki-67).
In addition, staining for laminin, a marker of the basement
membrane, revealed that the vascular architecture was mostly
intact in ACN/neo tumours, while aspects of focal basement
membrane destruction and alterations in the microvascular
architecture were frequent in the inner portion of ACN/IFN-g
tumour (Figure 6C, Laminin).
DISCUSSION
In this study, two human NB cell lines differing in their genetic
and phenotypic features were transfected with the human IFN-g
gene. These transfectants, which produced low amounts of the
cytokine in culture supernatants, displayed dramatic reduction in
their proliferation rate, increased expression of functional TNF-a
binding sites, HLA and CD40 surface molecules, similarly to that
observed in vitro following treatment of NB cell lines with
hrIFN-g (Ponzoni et al, 1992; Montaldo et al, 1994; Airoldi et al,
2003).
More interestingly, all these changes occurred, by a
paracrine mechanism, in parental cells cocultured with the
IFN-g transfectants. In addition, IFN-g-transfected ACN cells
showed a significantly reduced tumorigenicity, as compared to
parental and empty vector-transfected cells. This result was
obtained in a model, that is, human tumour cell xenograft in
nude mice, which precludes any effect of the transfected
cytokine on the mouse immune system, due to the species
specificity of human IFN-g. Thus, the slow proliferation rate of
NB cells observed in vivo was attributable to autocrine and
paracrine effects of the transfected cytokine on the tumour
cells themselves.
Since human IFN-g is species specific, the antiangiogenic effect
we observed likely resulted from anti-angiogenic mediators
produced by the tumour cells. The defective intratumoral
vascular network may lead to extensive necrosis followed by
reactive influx of phagocytosing cells. These results indicated that
IFN-g transfection of human NB cells may achieve not only
activation of immune antitumour responses, as already demon-
strated by others, but also affect NB tumour growth per se,b y
inhibiting NB proliferation and exploiting an antiangiogenic
effect.
Murine and human IFN-g gene-engineered NB cells have
already been produced (Watanabe et al, 1989; Coze et al, 1995;
Katsanis et al, 1995; Bausero et al, 1996). Murine IFN-g-
transfected NB cells were shown to induce specific CTL effectors
in tumour-bearing syngeneic mice (Watanabe et al, 1989). So far,
human IFN-g-transduced NB cells have been characterised in
vitro for phenotypic features (Coze et al, 1995; Ucar et al, 1995)
and ability to stimulate alloreactive T-cell responses in mixed
lymphocyte/tumour cell cultures (Coze et al, 1995; Coll et al,
1997).
The strategy of selecting low producing IFN-g-transfected NB
cells for this study was followed to prevent loss of transfectants, as
already described by others (Coze et al, 1995; Ucar et al, 1995), due
to the potent induction of NB tumour cell differentiation (Ponzoni
et al, 1992; Ponzoni et al, 1993; Montaldo et al, 1994) and
sensitisation to apoptosis (Fulda et al, 2001; Banelli et al, 2002;
Fulda and Debatin, 2002) caused by high level secretion of the
cytokine. The IFN-g-transfected NB cell lines described here have
been maintained in culture for prolonged period of time without
substantial changes in their characteristics.
Minimal amounts of IFN-g were indeed sufficient to induce
remarkable changes in surface expression of several molecules,
such as HLA, TNF-R and CD40, in cocultured parental NB cells
throughout paracrine mechanism. In this respect, we have recently
shown that incubation of CD40-positive NB cells with soluble or
insoluble CD40L leads to tumour cell apoptosis (Airoldi et al,
2003). These observations may be relevant in the perspective
of the design of a vaccination protocol for patients using alloge-
neic cell lines transfected with the human IFN-g gene. Thus, low-
dose IFN-g secreted by the latter cells locally injected at the tumour
resection site (where a few tumour cells may escape surgical
intervention) may promote presentation of peptide-derived
tumour-associated antigen to T lymphocytes leading to specific
anti NB responses. In addition, CD40L-induced apoptosis of
tumour cells may contribute to their elimination, provided that
CD40L-positive activated T lymphocytes are recruited to the
tumour site.
Furthermore, low secretion of IFN-g may help limit in vivo side
effects elicited by high doses of the cytokine, such as systemic
toxicity and altered T-lymphocyte polarisation and/or prolifera-
tion, as recently reported by Refaeli et al (2002).
Another issue here investigated is the expression of different
cytokine receptors in IFN-g-transfected cells. Notably, IL-11R and
IL-6R transcripts were clearly upregulated in transfected cells; both
IL-6 and IL-11 belong to the gp-130-associated family of
neuroactive cytokines. Furthermore, upregulation of the tran-
scripts for both chains of the IFN-gR was observed in transfected
cells, in accordance with previous studies. These results indicate
Transfection of NB cell lines with human IFN-c gene
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their sensitivity to other cytokines, possibly present in the tumour
microenvironment.
In conclusion, IFN-g-transfected allogeneic NB cell lines may be
envisaged as a delivery system of the cytokine to residual tumour
cells in a clinical setting. Low-dose IFN-g secretion would limit its
systemic toxicity while retaining most immunomodulatory and
antiangiogenic activities.
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